Akorn, Inc., a leading specialty pharmaceutical company, has launched the recently-approved 30 mg strength of Myorisan (isotretinoin capsules, USP). This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.

Akorn's Myorisan in 10 mg, 20 mg, 30 mg and 40 mg strengths, marketed under the VersaPharm label, are indicated for the treatment of severe recalcitrant nodular acne.

According to IMS Health, sales of 10 mg, 20 mg and 40 mg isotretinoin capsules were approximately $436 million for the twelve months ended July 31, 2015 while sales of the 30 mg strength were approximately $209 million over the same period.